Colorectal Cancer accounted for a 6.2% share of the global clinical trials within the Oncology therapy area in 2020, registering a decrease of 1.3% when compared with the last ten-year average of 7.5% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Colorectal Cancer
Industry sponsored trials held a 44.3% share of all the clinical trials for Colorectal Cancer indication in 2020, registering an increase of 8.2% when compared with the ten-year average of 36.1%. Non-industry sponsored trials accounted for a 55.7% share in 2020, marking a decrease of 8.2% over the ten-year average of 63.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Colorectal Cancer trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Colorectal Cancer trials, accounting for a 53.2% share in 2020, when compared with the five-year average of 47.8% and ten-year average of 43.1%.
North America was at the second position with a 50.4% share in 2020, over the five-year average of 57.8% and ten-year average of 55.4%, followed by Europe with a 25.2% share in 2020, as against five-year and ten-year averages of 38.6% and 41.3% respectively.
Middle East and Africa stood fourth with a 5.0% share in 2020, compared with the five-year average of 5.3% and ten-year average of 5.5%, followed by South and Central America with a 2.9% share in 2020, over five-year and ten-year averages of 3.7% and 3.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Colorectal Cancer trials, accounting for a 49.6% share in 2020, as against the five-year average of 57.5% and ten-year average of 54.2%.
China held a 28.1% share in 2020, over the five-year average of 19.3% and ten-year average of 13.4%, followed by Spain with a 12.2% share in 2020, compared with the five-year and ten-year averages of 21.1% and 19.4% respectively.
South Korea held a 10.1% share in 2020, as against the five-year average of 10.1% and ten-year average of 9.6%.
Germany held a 10.1% share in 2020, over the five-year and ten-year averages of 14.4% and 15.1% respectively.
Top regions of non-industry sponsored Colorectal Cancer trials
Asia-Pacific was the top region for non-industry sponsored Colorectal Cancer trials, accounting for a 60.2% share in 2020 when compared with the five-year average of 50.0% and ten-year average of 50.6%.
Europe was at the second position with a 22.3% share in 2020, over the five-year and ten-year averages of 27.8% and 27.6% respectively, followed by North America with an 18.1% share in 2020, as against the five-year average of 20.1% and ten-year average of 20.5%.
Middle East and Africa stood at the fourth position with a 0.6% share in 2020, compared with the five-year average of 3.0% and ten-year average of 2.2%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 1.0% and 1.1% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Colorectal Cancer trials, accounting for a 48.8% share in 2020, as against the five-year average of 26.8% and ten-year average of 18.1%.
The US held an 18.1% share in 2020, over the five-year average of 19.1% and ten-year average of 19.2%, followed by France with a 6.6% share, compared with the five-year and ten-year averages of 5.6% and 5.3% respectively.
Japan held a 5.4% share in 2020, as against the five-year average of 14.6% and ten-year average of 25.3%.
Denmark held a 4.2% share in 2020, over the five-year average of 2.7% and ten-year average of 2.0%.
Phase I trials lead industry sponsored clinical trials for Colorectal Cancer in 2020
Phase I trials held a 48.3% share of industry sponsored clinical trials for Colorectal Cancer in 2020, over the five-year average of 53.7% and ten-year average of 49.2%.
Phase II trials held a 40.8% share in 2020, as against the five-year average of 34.8% and ten-year average of 34.0%. Phase III trials held a 6.1% share in 2020, compared with the five-year and ten-year averages of 6.3% and 7.9% respectively.
Phase IV trials held a 4.8% share in 2020, over the five-year average of 5.2% and ten-year average of 9.0%.
Phase II trials lead non-industry sponsored clinical trials for Colorectal Cancer in 2020
Phase II trials held a 51.9% share of non-industry sponsored clinical trials for Colorectal Cancer in 2020, over the five-year average of 62.5% and ten-year average of 65.0%.
Phase I trials held a 23.2% share in 2020, as against the five-year average of 14.8% and ten-year average of 14.1%. Phase IV trials held a 13.0% share, compared with the five-year and ten-year averages of 11.1% and 10.3% respectively.
Phase III trials held a 11.9% share in 2020, over the five-year average of 11.6% and ten-year average of 10.6%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
